ALLK Stock Financial Analysis - Allakos Inc. (NasdaqGS) Stock

Overview

Allakos Inc. is a biopharmaceutical company based in the United States, specifically in Redwood City, California. It operates within the healthcare sector, focusing primarily on developing innovative therapeutics for allergic, inflammatory, and proliferative diseases. A key aspect of Allakos Inc.’s portfolio includes the development of monoclonal antibodies targeting siglec-8, an immune system receptor involved in the regulation of eosinophil and mast cell functions. These cells play crucial roles in the pathology of various diseases. The company’s most notable project includes the investigation of antolimab (AK002), their lead antibody, for conditions like eosinophilic gastritis, eosinophilic gastroenteritis, and other related disorders. Allakos Inc. is dedicated to addressing unmet medical needs in diseases associated with an overactive immune response.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted

Cash Flow: Operations, Investing, Financing

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV

Management Effectiveness

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC

Gross Margins

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin